Private industry—working in partnership with and receiving funding from the federal government—is playing an integral part in the United States' response to the COVID-19 pandemic and related economic challenges. Yet, these critical efforts may also expose companies to Congressional investigations and inquiries as House and Senate committees examine the federal response to the pandemic.
Congressional investigations present unique challenges and can have business, legal, policy, political, and public relations ramifications for individual companies and entire industries. In this webinar, a cross-disciplinary panel with a breadth of experience navigating complex and high-profile Congressional inquiries provide practical information regarding Congress' investigational jurisdiction, authorization and tactics, as well as share best practices for managing these inquires and mitigating collateral risks.
While this program will highlight issues that may be particularly pertinent in the context of the COVID-19 pandemic, it will provide insights generally applicable to Congressional investigations.
Originally published May 21, 2020
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
